Cochrane · systematic review · CD010226
Trifluoperazine versus placebo for schizophrenia
Koch, K, Mansi, K, Haynes, E, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 14.3%Very low 4 · 57.1%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
TRIFLUOPERAZINE versus PLACEBO for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state ‐ clinical improvement ‐ medium term As defined by each study TRIFLUOPERAZINE vs PLACEBO | RR 4.61 [1.54, 13.84] | 3 studies · 417 participants | Low Downgraded: risk of bias, indirectness |
Global state ‐ relapse or worsening ‐ medium term Numbers of participants experiencing relapse/worsening TRIFLUOPERAZINE vs PLACEBO | RR 0.34 [0.23, 0.49] | 2 studies · 381 participants | Low Downgraded: risk of bias, indirectness |
Mental state ‐ any clinically significant response in psychotic symptoms (as defined by each study) ‐ medium term Numbers of participants experiencing 'intensified symptoms' TRIFLUOPERAZINE vs PLACEBO | RR 1.05 [0.54, 2.05] | 2 studies · 80 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Leaving the study early ‐ any reason ‐ medium term Number of participants leaving the studies early TRIFLUOPERAZINE vs PLACEBO | RR 0.67 [0.38, 1.19] | 5 studies · 523 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Severe adverse effects ‐ short term Numbers of participants leaving the studies due to severe adverse effects TRIFLUOPERAZINE vs PLACEBO | RR 1.31 [0.22, 7.8] | 2 studies · 67 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Behaviour ‐ any clinically significant agitation or distress ‐ medium term As defined by each study TRIFLUOPERAZINE vs PLACEBO | RR 2 [0.19, 20.72] | 1 study · 52 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Economic outcomes TRIFLUOPERAZINE vs PLACEBO | no estimate extracted | 0 studies · 0 participants | Ungraded |